MAR 23, 2020
Cataract/Anterior Segment, Comprehensive Ophthalmology
This is one of the largest studies to investigate the use of prophylactic intracameral moxifloxacin for preventing postoperative endophthalmitis.
Investigators retrospectively analyzed more than 2 million consecutive phacoemulsification and manual small-incision (MSICS) procedures performed in Aravind Eye Hospitals in India during an 8-year period. The primary outcome was rate of postoperative endophthalmitis in uncomplicated and complicated eyes with and without intracameral moxifloxacin prophylaxis (ICMP).
The overall rate of endophthalmitis significantly declined from 0.07% to 0.02% with intracameral moxifloxacin, regardless of the type of surgery. Moxifloxacin was particularly beneficial in eyes with complications such as posterior capsule rupture, significantly cutting infection rates in both the MSICS (0.54% vs. 0.26%) and phaco (0.29% vs. 0.06%) groups when compared with untreated eyes.
This study is retrospective, which introduces variables that wouldn't have been in a prospective randomized controlled trial. The differences in surgical techniques between surgeons is also a limiting factor.
This study adds more evidence that highlights the usefulness of intracameral antibiotics for reducing endophthalmitis risk. These data are convincing that intracameral moxifloxacin is a good antibiotic choice for preventing postoperative endophthalmitis.